Erster Malaria-Impfstoff von der WHO für Kinder empfohlen

Yesterday, the World Health Organization (WHO) recommended the widespread use of the malaria vaccine RTS,S/AS01, debuting a tool that could save the lives of tens of thousands of children in sub-Saharan Africa each year. The vaccine is not just a first for malaria - it is the first developed for any parasitic disease. This day was made possible through decades-long research and teaching commitments to advance malaria eradication. The World Health Organization (WHO) endorsed the widespread use of the malaria vaccine RTS,S/AS01, marking the first step in a process that should lead to broad distribution in lowand middle-income countries. With a moderate efficacy of preventing 39% of malaria cases, the vaccine assists a child's immune system to prevent an infection by Plasmodium falciparum , the deadliest of the five malaria pathogens and the most common in Africa. Swiss TPH has played a leading role in this day coming to fruition thanks to decades of research and development of new malaria vaccines. Researchers at Swiss TPH contributed across the entire development pathway from discovery to preclinical studies, and through to human clinical testing in both early and late studies with many African collaborators.